Study identifier:SH-NEG-0004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
On demand vs continous treatment of endoscopy negative subjects with gastroesophageal reflux disease (GERD) with esomeprazole 20 mg o.d. over a 6 months long term treatment phase. An open, randomised, multicenter study - NEED
gastrointestinal diseases
Phase 3
-
-
-
-
Interventional
-
Allocation: - 
Endpoint Classification: - 
Intervention Model: - 
Masking: - 
Primary Purpose: - 
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
| Arms | Assigned Interventions | 
|---|